Ambalal Sarabhai Peer Comparison

NSE: AMBASARABH | BSE: 500009

₹37.89

₹-1.65 (-4.17%)

As on 01-Oct-2026IST

Market cap

₹291 Cr

Revenue (TTM)

₹206 Cr

P/E Ratio

21.4

P/B Ratio

1.8

Div. Yield

0 %

Edit

	Ambalal Sarabhai	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	291	20,009	20,803	17,636	16,508
Revenue (₹ Cr)	206	2,287	1,682	2,570	3,230
Net Profit (₹ Cr)	12.68	678.07	273.51	735.15	666.92
Net Margin (%)	5.92	28.10	16.19	26.88	20.60
RoE (%)	9.33	19.73	11.15	19.16	18.75
Price to Earnings	21.44	30.07	69.97	23.99	25.64
Price-To-Book	1.79	5.45	7.74	4.00	4.09

Income Statement (₹ Cr)

	Ambalal Sarabhai	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Operating Revenue	205.50	2,287.33	1,682.47	2,569.77	3,229.67
Total Income	214.34	2,413.29	1,689.83	2,735.39	3,237.12
Total Expenditure	190.67	1,490.75	1,203.91	1,628.14	2,090.06
EBITDA	14.82	796.58	478.55	941.63	1,139.61
Depreciation	4.41	78.10	126.01	57.58	281.06
EBIT	10.41	718.48	352.55	884.05	858.55
Interest	4.06	0.88	52.11	7.69	190.64
Other Income	8.84	125.96	7.37	165.62	7.45
Exceptional Items	-0.82	0.00	12.16	-49.16	-17.24
Profit before Tax	14.38	843.56	319.96	992.82	658.12
Provision for Tax	1.70	165.49	46.45	257.67	-8.80
Profit after Tax	12.68	678.07	273.51	735.15	666.92

	Ambalal Sarabhai	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Shareholder's Funds	158.36	3,586.42	2,591.20	4,202.90	3,902.67
Minority Interest	0.00	-12.71	0.00	0.00	-21.81
Non-Current Liabilities	24.22	28.74	266.35	91.50	1,392.75
Current Liabilities	98.54	385.94	848.06	627.48	2,077.10
Total Liabilities	279.53	4,037.51	3,705.61	4,921.88	7,246.72

	Ambalal Sarabhai	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Non-Current Assets	123.88	1,291.22	2,525.44	770.28	5,617.77
Current Assets	125.03	2,585.66	1,109.77	3,803.22	1,539.85
Total Assets	279.53	4,037.51	3,705.61	4,921.88	7,246.72
Total Debt*	51.65	0.57	657.97	2.50	2,309.68
Net Current Assets	26.49	2,199.72	261.71	3,175.74	-537.25
Contingent Liabilities	38.57	17.53	160.01	370.49	51.57

	Ambalal Sarabhai	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Cash From Operating Activities	13.40	523.24	342.18	967.57	537.99
Cash Flow from Investing Activities	-10.25	-582.30	-325.92	-561.67	-369.46
Cash from Financing Activities	-1.85	-46.46	13.62	-798.31	-313.53
Net Cash Inflow / Outflow	1.30	-105.52	29.88	-392.41	-145.00

	Ambalal Sarabhai	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
ROCE (%)	11.52	24.97	11.43	23.39	14.47
ROE (%)	9.33	19.73	11.15	19.16	18.75
ROA (%)	4.60	18.69	7.80	14.95	9.26
EBIT Margin (%)	5.07	31.41	20.95	34.40	26.58
Net Margin (%)	5.92	28.10	16.19	26.88	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Ambalal Sarabhai	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Revenue Growth (%)	4.94	15.01	27.91	10.69	9.59
EBIT Growth (%)	116.17	18.45	58.32	24.14	16.84
Net Profit Growth (%)	7.23	19.61	149.56	-9.09	62.68
EPS Growth (%)	3.59	17.73	-3.57	14.40	67.41
Book Value Growth (%)	13.13	26.75	9.67	-0.34	36.71

	Ambalal Sarabhai	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Price / Earnings	20.37	30.07	74.22	22.86	24.99
Price / Book Value	1.79	5.45	7.74	4.00	4.09
Dividend Yield (%)	0.00	0.30	0.06	1.95	0.00
EV/EBITDA	21.78	23.86	44.75	15.43	16.45
Market Cap (₹ Cr)	185.99	11,439.22	6,819.66	21,592.90	17,980.08

	Ambalal Sarabhai	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debt to Equity	0.11	0.00	0.07	0.00	0.24
Short term debt to equity ratio	0.19	0.00	0.16	0.00	0.12
Current Ratio	1.27	6.70	1.31	6.06	0.74
Quick Ratio	1.04	5.59	0.88	5.31	0.53
Interest Coverage	4.54	959.59	7.14	130.11	4.45

	Ambalal Sarabhai	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debtors to sales (%)	23.21	36.10	30.84	7.07	21.07
Asset Turnover	0.75	0.63	0.48	0.52	0.45
Receivable days	80.44	121.68	113.81	26.06	63.88
Inventory Days	40.16	63.83	84.76	65.95	43.27
Payable days	139.22	108.28	101.94	81.01	151.85
Cash Conversion Cycle	-18.62	77.23	96.62	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.